24th Jan 2014 11:01
LONDON (Alliance News) - Shares in e-Therapeutics PLC dropped 16% Friday morning after it said that it was temporarily halting recruitment into its ETS2101 cancer trials due to a drug supply issue.
e-Therapeutics said that there had been a practical issue with the stored drugs for the trials, and as a result it would halt recruitment for patients in both of the ongoing phase I trials of the treatment. Patients already under treatment will continue to be dosed under the trial.
The company said it was taking steps to resume recruitment as soon as possible.
Shares in e-Therapeutics were trading down 16% at 22.50 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
ETX.L